Sign in
4

Changes in Ownership

Aurinia Pharmaceuticals Inc. Filed Acc 0001628280-21-019051

EVP of Research sold 32,500 shares at an average $23.99 ($779,533)

  • EVP of Research acquired 27,136 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Huizinga Robert Bindert · EVP of Research

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2021-09-21 Exercise or conversion : show line 1 in the form +16,000 $2.63 $42,080 122,092 D
2021-09-21 Exercise or conversion : show line 2 in the form +11,136 $3.20 $35,635 133,228 D
2021-09-21 Sale : show line 3 in the form −27,136 $24.05 $652,621 106,092 D
2021-09-21 Sale : show line 4 in the form −5,364 $23.66 $126,912 100,728 D
Open-market sales · 32,500 sh · avg $23.99 · $779,533

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2021-09-21 Exercise or conversion : show line 5 in the form Stock Option (right to buy) −16,000 0 D
2021-09-21 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −11,136 98,864 D
Loading xslF345X03/wf-form4_163234399960979.xml…